Goldman Sachs Alternatives

Alternative investments arm of Goldman Sachs, active here through its growth equity and life sciences teams.

Profile being verified

Stage
Series B to Series C across recorded rounds
Ticket
Ticket sizes not disclosed; recorded rounds of USD 100 M to USD 152 M
Location
Not specified
Tracked rounds
2

What they look for

Led the USD 100 M Series C of Neural Concept (Growth Equity team) and co-led the USD 152 M Series B of Vaderis Therapeutics with TCGX (Life Sciences team), where Colin Walsh sits on the board.

Recent investments

Recorded Swiss rounds: Neural Concept (Series C, USD 100 M, December 2025, lead), Vaderis Therapeutics (Series B, USD 152 M, August 2026, co-lead).

Rounds tracked by FundSwiss